(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) fell by a staggering 28.85% in 21 sessions from €0.13 to €0.09 at 05:10 EST on Monday, following the last session’s downward trend. BEL 20 is sliding 0.69% to €3,523.37, after five consecutive sessions in a row of losses.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures' and ArsciCor, which is in Phase III in GvHD is being prepared with an oral treatment. BioSenic S.A. is based in Mont-Saint-Guibert, Belgium.
Earnings Per Share
As for profitability, BIOSENIC has a trailing twelve months EPS of €-0.01.
Volume
Today’s last reported volume for BIOSENIC is 230992 which is 94.77% below its average volume of 204507.
More news about BIOSENIC (BIOS.BR).
